Trial
NCT04910269
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Phase IIISUSPENDEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University of Minnesota
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
Condition
COVID
Intervention
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Why stopped
Stopped for futility - no safety issues.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-01